araag2/HINT huggingface dataset:
Clinical trial NCT02856555 (phase 2, status: completed)
Conditions: nonalcoholic steatohepatitis (nash)
ICD codes: K75.81
Drugs: firsocostat, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Meets all of the following conditions:

               -  A clinical diagnosis of nonalcoholic fatty liver disease (NAFLD)

               -  Screening magnetic resonance imaging - proton density fat fraction (MRI-PDFF)
                  with ≥ 8% steatosis

               -  Screening magnetic resonance elastography (MRE) with liver stiffness ≥ 2.5 kPa

                    -  OR

               -  A historical liver biopsy consistent with NASH and non-cirrhotic fibrosis

          -  Platelet count ≥ 100,000/mm^3

          -  Creatinine Clearance (CLcr ) as calculated by the Cockcroft-Gault equation ≥ 60 ml/min

        Key Exclusion Criteria:

          -  Pregnant or lactating females

          -  Alanine aminotransferase (ALT) > 5 x upper limit of the normal range (ULN)

          -  Other causes of liver disease including autoimmune, viral, and alcoholic liver disease

          -  Cirrhosis of the liver

               -  Prior history of decompensated liver disease, including ascites, hepatic
                  encephalopathy or variceal bleeding

          -  Body mass index (BMI) < 18 kg/m^2

          -  International normalized ratio (INR) > 1.2 unless on anticoagulant therapy

          -  Total bilirubin > 1 x ULN, except with diagnosis of Gilbert's syndrome

        NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Clinical trial NCT02857426 (phase 2, status: active, not recruiting)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: nivolumab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Pathologically confirmed PCNSL or PTL who failed or did not respond to at least 1 line
             of systemic therapy

          -  Measurable disease requirements on scans:

        PCNSL subjects should have at least one measurable extranodal brain lesion; PTL subjects
        should have at least 1 measurable extranodal lesion or nodal lesion

          -  Have tumor tissue for PD-L1 expression testing

          -  Must have a Karnofsky performance status of 70-100

        Exclusion Criteria:

          -  a) Intraocular PCNSL without evidence of brain disease b) PCNSL patients who cannot
             undergo MRI assessments c) PCNSL patients with systemic disease

          -  Patients with certain diseases such as active autoimmune disease, type I diabetes,
             hypothyroidism that needs hormone replacement, active infection, psychiatric disorder

          -  Prior malignancy active within the previous 3 years except for locally curable cancers
             that have been apparently cured, such as basal or squamous cell skin cancer,
             superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast

          -  Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4
             antibody, or any other antibody or drug specifically targeting T-cell co-stimulation
             or checkpoint pathways

        PCNSL, and PTL subjects with brain or spinal cord lesion who have received doses of more
        than 2 mg/day of dexamethasone or equivalent within the 14 days period prior to the first
        dose of nivolumab are excluded

        Other protocol defined inclusion/exclusion criteria could apply
Clinical trial NCT02864381 (phase 2, status: completed)
Conditions: gastric adenocarcinoma, gastroesophageal junction adenocarcinoma
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: andecaliximab, nivolumab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Key Inclusion Criteria:

          -  Histologically confirmed inoperable locally advanced or metastatic adenocarcinoma of
             the stomach or GEJ which have progressed on at least 1 prior systemic therapy or line
             of treatment for unresectable/metastatic disease

          -  Eastern Cooperative Oncology Group (ECOG) performance score of ≤ 1

          -  Measurable disease according to Response Criteria in Solid Tumors (RECIST) v1.1

          -  Tumor sites that can be accessed for repeat biopsies

          -  Archival tumor tissue, preferably obtained from the most recent available biopsy;
             there must be adequate tissue for a Cochran-Mantel Haenszel (CMH) test stratified by
             programmed death ligand 1 (PD-L1) stratification test, as assessed by central
             pathologist

          -  Individuals not receiving anticoagulant medication must have an international
             normalized ratio (INR) ≤ 1.5 and activated partial thromboplastin (aPTT) ≤ 1.5 x upper
             limit of normal (ULN)

          -  Required baseline laboratory data as outlined in protocol

        Key Exclusion Criteria:

          -  Individuals who have received only neoadjuvant or adjuvant therapy for gastric
             adenocarcinoma

          -  Radiotherapy within 28 days of randomization

          -  Uncontrolled intercurrent illness as outlined in protocol

          -  History of a concurrent or second malignancy except for those outlined in protocol

          -  Major surgery, within 28 days of first dose of study drug

          -  Known positive status for human immunodeficiency virus (HIV)

          -  Known acute or chronic-active infection with hepatitis B virus (HBV) or hepatitis C
             virus (HCV)

          -  Chronic daily treatment with oral corticosteroids (dose of > 10 mg/day prednisone
             equivalent) or other immunosuppressive medications within 14 days of randomization

          -  Known or suspected central nervous system metastases

          -  Documented myocardial infarction or unstable/uncontrolled cardiac disease within 6
             months of randomization

          -  Serious systemic fungal, bacterial, viral, or other infection that is not controlled
             or requires intravenous antibiotics

          -  Current or history of pneumonitis or interstitial lung disease

          -  Active known or suspected autoimmune disease with exceptions noted in protocol.

          -  History of bone marrow, stem cell, or allogenic organ transplantation

        NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Clinical trial NCT02865122 (phase 2/phase 3, status: terminated)
Conditions: short bowel syndrome
ICD codes: D68.61, D69.41, D81.4, E24.1, E26.01, E26.81, E34.0
Drugs: ntra-9620, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    sponsor decision based on enrollment
  
Eligibility criteria:

        Inclusion Criteria

          1. Subject must be at least 28 weeks post-menstrual age and up to 52 weeks chronological
             age at enrollment.

          2. Subject weight must be at least 500 grams (17.6 ounces) at time of enrollment.

          3. After major surgical resection leading to SBS, the subject has maximally 70% of
             expected bowel length preserved or an ostomy in place such that ≤ 70% of the small
             bowel is available for nutrient absorption.

        Exclusion Criteria

          1. Subject has undergone any bowel lengthening procedure.

          2. Subject has a malabsorption disorder due to:

               -  congenital etiology (such as microvilli inclusion disease, tufting enteropathy)

               -  Untreated Hirchsprung's disease

          3. Uncontrolled systemic infection, acute gastroenteritis, pneumonia, cardiovascular or
             other abnormality including EKG findings that in the opinion of the investigator makes
             the infant unstable and at significant risk of not completing first 12 weeks of the
             study.

          4. Subjects with hyperinsulinemia.

          5. Subjects with unexplained or recurrent hypoglycemia with blood glucose ≤ 50 mg/dL
             within 48 hours of treatment initiation.
Clinical trial NCT02867956 (phase 2, status: completed)
Conditions: ovarian cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: apatinib, etoposide
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or pathologically confirmed diagnosis of epithelial carcinoma of the
             ovary.

          -  Platinum resistant ovarian cancer (defined as relapsing within 6 months after the last
             administration of platinum-based chemotherapy) OR platinum refractory ovarian cancer
             (defined as progressing while on a platinum-based chemotherapy)

          -  At least treated with one line of platinum-based chemotherapy

          -  Female, age ≥18 years and ≤70 years, signed informed consent.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST)
             1.1 version

          -  Patients must have a life expectancy of at least 3 months.

          -  Patients must have adequate organ function as defined by the following criteria:

               -  White blood cell count ≥ 3 x 10^9/L, Absolute neutrophil count (ANC) (≥ 1.5 x
                  10^9/L), Hemoglobin of ≥ 80 g/L, Platelets ≥ 70 x 10^9/L

               -  Total bilirubin ≤ 1 x upper limit of normal (ULN), AST and ALT ≤ 2 x ULN

               -  Serum creatinine ≤ 1 x ULN

        Exclusion Criteria:

          -  Had prior exposure to apatinib or has known allegies to any of the excipients.

          -  History of myocardial infarction, or unstable angina, or New York Heart Association
             (NYHA) Grade III-IV within 6 months prior to Day 1.

          -  Patients with QT interval prolongation

          -  Serious, non-healing wound, active ulcer, bowel obstruction.

          -  History of abdominal fistula or gastrointestinal perforation within 28 days prior to
             Day 1

          -  Evidence of bleeding diathesis or coagulopathy

          -  Inadequately controlled hypertension

          -  Major surgical procedure within 28 days prior to Day 1

          -  Symptomatic central nervous system (CNS) metastasis
Clinical trial NCT02869347 (phase 2, status: completed)
Conditions: acute kidney injury
ICD codes: N26.2, Q63.0, Q63.2, Z52.4, I75.81, N19, N20.0
Drugs: conestat alfa, sodium chloride 0.9%
SMILES: [Na+].[Cl-]
Eligibility criteria:

        Inclusion Criteria:

          -  Estimated glomerular filtration rate (eGFR) of <50 ml/min/1.73m2

          -  At least one of the following risk factors: diabetes mellitus, age at least 75 years,
             anemia (baseline hematocrit value less or equal 39% for men and less or equal 36% for
             women), congestive heart failure class III or IV by New York Heart Association
             classification, history of pulmonary edema.

        Exclusion Criteria:

          -  Contraindications to the class of drugs under study (C1 esterase inhibitors), e.g.
             known hypersensitivity or allergy to class of drugs or the investigational product

          -  History of allergy to rabbits

          -  Current treatment with N-acetylcysteine, sodium bicarbonate, fenoldopam, mannitol (not
             applicable to mannitol serving as excipient in other medical drugs), dopamine or
             theophylline

          -  Women who are pregnant or breast feeding

          -  Multiple myeloma

          -  Acute decompensated heart failure (requiring hospital admission and treatment with
             supplemental oxygen, diuretics and/or vasodilator therapy) within two weeks prior to
             the date of coronary angiography

          -  Acute myocardial infarction (ST elevation or non-ST elevation myocardial infarction)
             within two weeks prior to the date of coronary angiography

          -  Dialysis

          -  Exposure to iodinated contrast media within seven days prior to the date of coronary
             angiography.

          -  Participation in another study with investigational drug within the 30 days preceding
             and during the present study

          -  Previous enrolment into the current study

          -  Enrolment of the investigators and their family members
Clinical trial NCT02873338 (phase 2, status: completed)
Conditions: acute myeloid leukemia
ICD codes: C92.A1, C92.A2, C92.61, C92.62, C92.A0, C92.60
Drugs: cx-01, idarubicin, cytarabine
SMILES: [H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  Newly diagnosed, de novo or secondary, previously untreated AML

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

        Exclusion Criteria:

          -  Acute promyelocytic leukemia

          -  Prior chemotherapy for AML

          -  Prior intensive chemotherapy or stem cell transplantation for the treatment of
             myelodysplastic syndrome

          -  CNS leukemia
Clinical trial NCT02874846 (phase 2, status: completed)
Conditions: ocular hypertension, open angle glaucoma
ICD codes: H40.053, H40.051, H40.052, H40.059, H40.10X0, H40.10X1, H40.10X2, H40.10X3, H40.10X4, H40.1130, H40.1131
Drugs: netarsudil ophthalmic solution 0.02%
SMILES: CC1=CC(C)=C(C=C1)C(=O)OCC1=CC=C(C=C1)[C@@H](CN)C(=O)NC1=CC=C2C=NC=CC2=C1
Eligibility criteria:

        Inclusion Criteria:

          1. 18 years of age or older.

          2. Ocular hypertension or open-angle glaucoma in both eyes.

          3. Unmedicated intraocular pressure > 17 mmHg in one or both eyes and < 30 mmHg in both
             eyes.

          4. Corrected visual acuity in each eye equivalent to 20/200 or better.

          5. Able and willing to give signed informed consent and follow study instructions.

        Exclusion Criteria:

          1. Glaucoma with pseudoexfoliation or pigment dispersion component, history of angle
             closure, narrow angles.

          2. Intraocular pressure ≥ 30 mmHg.

          3. Use of ocular medications within 30 days.

          4. Known hypersensitivity to any component of the test formulations or to medications
             used routinely during a clinical eye examination.

          5. Previous eye surgery (other than cataract).

          6. Ocular trauma within 6 months.

          7. Clinically significant ocular disease that might interfere with the study.

          8. Central corneal thickness greater than 620 µm.
Clinical trial NCT02878330 (phase 2, status: completed)
Conditions: respiratory syncytial virus infections
ICD codes: R09.2, A15.7, A15.8, A15.9, J98.9, R06.03, J12.1
Drugs: medi8897, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          1. Healthy infants born between 29 weeks 0 days and 34 weeks 6 days GA.

          2. Infants who are entering their first full RSV season at the time of screening.

        Key Exclusion Criteria:

          1. Meets American Academy of Pediatrics (AAP) or other local criteria to receive
             commercial palivizumab.

          2. Any fever (>= 100.4°F [>= 38.0°C], regardless of route) or lower respiratory illness
             within 7 days prior to randomization.

          3. Acute illness (defined as the presence of moderate or severe signs and symptoms) at
             the time of randomization.

          4. Active RSV infection (a child with signs/symptoms of respiratory infection must have
             negative RSV testing) or known prior history of RSV infection.

          5. Receipt of palivizumab or other RSV monoclonal antibody or any RSV vaccine, including
             maternal RSV vaccination.
Clinical trial NCT02885181 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: gs-9876, filgotinib, gs-9876 placebo, filgotinib placebo, methotrexate
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Active RA disease as defined by: a tender joint count (TJC) of ≥ 6 (out of 68), a
             swollen joint count (SJC) of ≥ 6 (out of 66) at screening and Day 1

          -  Inadequate response to treatment with oral or parenteral methotrexate (MTX) 7.5 to 25
             mg/week continuously for at least 12 weeks

          -  No evidence of active or latent tuberculosis

        Key Exclusion Criteria:

          -  Prior treatment with B-cell depleting agents (eg, rituximab), unless more than 6
             months prior to the first dose of study drug and documented return of CD19+ cells at
             screening

          -  Prior treatment with any commercially available or investigational spleen tyrosine
             kinase (SYK) inhibitor

          -  Concurrent treatment with any other conventional synthetic DMARD (csDMARD) other than
             MTX and/or hydroxychloroquine (HCQ) (prior csDMARD treatment allowed if appropriate
             wash out as defined in the protocol)

          -  Concurrent treatment with any biological disease modifying anti-rheumatic drug
             (bDMARD)(prior bDMARD treatment allowed if appropriate wash out as defined in the
             protocol). Prior failure to treatment with bDMARDs is not an exclusion criterion.

        Note: Other protocol defined Inclusion/ Exclusion criteria may apply.
Clinical trial NCT02888236 (phase 2, status: completed)
Conditions: psoriasis vulgaris
ICD codes: L40.0
Drugs: leo 32731, leo 32731 placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Signed and dated informed consent

          -  Aged between 18 years and 65.

          -  Males or females of non-childbearing potential.

          -  Clinical diagnosis of psoriasis vulgaris with or without psoriatic arthritis

          -  Have moderate to severe psoriasis vulgaris

          -  Candidates of systemic anti-psoriatic treatment and/or phototherapy

        Exclusion Criteria:

          -  Subjects with therapy resistant psoriasis

          -  Previously exposed to apremilast

          -  Systemic treatment with biological therapies, whether marketed or not, with a possible
             effect on psoriasis vulgaris

          -  Systemic treatment with all other therapies (other than biologics) with a possible
             effect on psoriasis vulgaris
Clinical trial NCT02889549 (phase 2/phase 3, status: unknown status)
Conditions: coronary artery disease
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118
Drugs: ticagrelor, clopidogrel
SMILES: [H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Stable Coronary Artery Disease (1) stable angina (2) low-risk unstable angina (3)
             variant angina (4) patients with asymptomatic with appropriate therapy（including
             percutaneous coronary intervention）

          2. Diabetes

        Exclusion Criteria:

          1. ACS

          2. planned use of glycoprotein IIb/IIIa receptor inhibitors, adenosine diphosphate (ADP)
             receptor antagonists, aspirin or anticoagulant therapy during the study period

          3. platelet count <100g/L

          4. creatinine clearance rate < 30ml/min

          5. diagnosed as respiratory or circulatory instability (cardiac shock, severe congestive
             heart failure NYHA II-IV or left ventricular ejection fraction < 40%)

          6. a history of bleeding tendency

          7. ticagrelor or clopidogrel allergies
Clinical trial NCT02891226 (phase 2, status: active, not recruiting)
Conditions: crohn's disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: mirikizumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Active Crohn's Disease (CD) as determined by the SES-CD, and participant reported
             stool frequency and abdominal pain.

          -  Inadequate response or failure to tolerate at least one of the following:
             aminosalicylates; budesonide; systemic corticosteroids; immunosuppressants (eg,
             azathioprine, 6-mercaptopurine, or methotrexate); or prior exposure to biologics for
             the treatment of CD.

        Exclusion Criteria:

          -  Have complications of CD such as strictures, stenoses, or any other manifestation for
             which surgery might be indicated, or that could confound the evaluation of efficacy.

          -  Diagnosis of conditions affecting the digestive tract, such as ulcerative colitis,
             indeterminate colitis, fistulizing disease, abdominal or perianal abscess, adenomatous
             colonic polyps not excised, colonic mucosal dysplasia, and short bowel syndrome.

          -  Have had any kind of bowel resection, diversion, or placement of a stoma within 6
             months or any other intra-abdominal surgery within 3 months prior to screening.

          -  Are unsuitable for inclusion in the study in the opinion of the investigator or
             sponsor for any reason that may compromise the subject's safety or confound data
             interpretation.